Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, has named Kim Sablich as its new executive vice president, general manager of North America, effective 1 June 2020, it was reported on Monday.

In the new role, Sablich will lead company's newly formed North American regional business structure, which includes Canada and the United States, and which combines Medical Affairs, Commercial and Market Access teams for North America. Sablich will report to Daniel Swisher, president and chief operating officer.

Prior to joining Jazz Pharmaceuticals plc, Sablich has served Myovant Sciences as chief commercial officer. Before joining Myovant Sciences, she was vice president, Primary Care Marketing in the United States for GlaxoSmithKline. Her previous role in the company included vice president, Global Medicines Commercialisation in the UK and vice president, Vaccines Commercial Strategies. Prior to her career time at GlaxoSmithKline, she spent 15 years at Merck where she held positions of increasing responsibility in the commercial organisation across sales, product management, consumer marketing, pricing/access, and customer insights/analytics, with a focus on the cardiovascular, respiratory, women's health and vaccines business areas. Sablich has extensive experience in direct-to-consumer marketing. Presently, she serves on the AllerGenis LLC board of directors.